For security, Pfizer watches suppliers

"Do not enter into supply agreements with companies that do not meet acceptable standards, and terminate agreements with companies that do not maintain acceptable standards." So says Gerry Migliaccio, senior VP for global manufacturing at Pfizer, in a Pharmaceutical Technology interview.

He says that's an oversimplification of one of the key elements of enforcement in a strategy for supply-chain security. Many factors are involved in evaluating suppliers, notes Migliaccio. But once basic viability has been established, he looks at their quality systems and environmental-management systems.

Migliaccio also notes in the interview that control of the suppliers to Pfizer's suppliers is among then most critical of supply chain security issues.

- see the article

Suggested Articles

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.

Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S.